Biocon Biologics Inc

Tevard Biosciences Inc., based in Cambridge, MA, is a biotechnology company focused on developing transformative tRNA-based therapies aimed at curing a wide range of genetic disorders, particularly those caused by nonsense mutations. Founded by MIT Professor Harvey Lodish, along with parents Daniel Fischer and Warren Lammert, the company is driven by a mission to address the unmet medical needs of patients with rare diseases, including conditions like Dravet syndrome, Duchenne muscular dystrophy, and various developmental and epileptic encephalopathies. Utilizing its proprietary tRNA platform, Tevard aims to restore full-length proteins critical for proper cellular function, with a therapeutic approach that is broadly applicable across different diseases. The company's innovative solutions offer the potential for durable cures and are being evaluated in preclinical and clinical settings to provide new hope for patients affected by severe genetic disorders. Generated from the website

In operation since 1981, Genzyme Corporation is one of the leading biotechnology companies in the world. The company employs a staff of more than 12,000 people and manages over 85 locations in nearly 40 countries. It focuses on the areas of hematologic oncology, biosurgery, transplant, genetic diseases, and cardiometabolic and renal. Genzyme Corporation offers Fabrazyme, which is a solution for intravenous infusion. The company also provides Fabrazyme, Renagel, Renvela and Hectorol. It offers solutions for the medical and patient communities. In addition, Genzyme Corporation offers Synvisc, which is a viscosupplementation treatment for relieving knee pain associated with osteoarthritis. The company provides Sepra, which is a line of hyaluronic acid-based products.

Biogen Inc, located in Cambridge, MA, is a biotechnology company dedicated to discovering and developing transformative medicines for neurological and neurodegenerative diseases, including Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The company emphasizes its commitment to innovation, health equity, and corporate responsibility, striving to make a meaningful impact on patients' lives through science and research. With a focus on collaboration and a diverse workforce, Biogen fosters an inclusive culture that encourages employees to tackle complex challenges in healthcare. The company is also actively engaged in community initiatives and sustainability efforts, reflecting its mission to not only advance medical science but also support broader societal goals. Generated from the website